Gilead Sciences — HIV Medication Kickbacks
Gilead Sciences Pays $202 Million for Speaker Program Kickbacks
Source: U.S. Department of Justice
TL;DR: Gilead Sciences Pays $202 Million for Speaker Program Kickbacks This case resulted in a $202 Million resolution and demonstrates the impact of whistleblower protections in recovering funds from fraud.
Summary
Gilead Sciences agreed to pay $202 million to resolve allegations that it funneled kickbacks in the form of speaker fees, costly meals, and travel expenses to physicians to induce them to prescribe its HIV medications. DOJ alleged the company's speaker programs were used as vehicles for improper remuneration rather than legitimate educational purposes, with payments tied to prescribing volume rather than genuine speaking services.
Our Take
Speaker program kickback cases often reveal a pattern where "education" is really marketing and "honoraria" are really inducements. Insiders typically have the most useful evidence: speaker selection criteria tied to prescribing potential, program attendance lists showing the same physicians repeatedly, meal and travel spending that exceeds any educational value, and internal metrics linking speaker payments to prescription growth. If you've seen speaker programs where the real purpose is clearly revenue generation, document the selection process, the payment structures, and any communications acknowledging the true intent.
Read the full article from the original source:
View Original ArticleOpens in a new tab. Content from U.S. Department of Justice.
Notice
The summaries above are based on publicly available information released by the U.S. Department of Justice and are provided for informational purposes only. They do not constitute legal advice, investigative findings, or allegations by Disclosure Strategy. Our commentary reflects general, experience-based observations about how False Claims Act matters commonly arise and is not a statement about any party's liability.